										Sheet 1 of 1
Based on Form PTO-1449 (3/90)						ATTY. DOCKET NO.	SERIAL NO.			
OIPE						671308-2001.	10/782,899			
LIST OFFEFERENCES CITED BY APPLICANT SEP 2 8 2005 (Use several sheets if necessary)						аррысалт FUJIMORI, ET AL				
					-	FILING DATE	GROUP			
TA TRADENASTIS						FEBRUARY 23,	1635			
		· · · · ·			U.S. PATENT	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER		DATE	DATE NAME		CLASS	SUBCLASS FILING DATE IF APPROPRIATE			
•										
		1			-					
•					· · · ·	· ·			· · · · · · · · · · · · · · · · · · ·	
··	L	1	FOREIG	N PATENT DOCUI	MENTS					
		DOCUMENT NUMBER		DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION	
									YES	NO
	· · ·									
							· · · · · · · · · · · · · · · · · · ·			
						<u></u>				
			OT	HER REFERENCE	S (Including A	Author, Title, Date, Pertinent Pag	es, Etc.)			
SL		Li X, Fu inhibitor	GF, Fan YR, of angiogenes	Liu WH, Liu XJ, Wasis and hypoxic tumo	ang JJ, Xu QX r growth. Can	Bifidobacterium adolescentis a cer Gene Ther. 2003 Feb;10(2):1	s a delivery syste 05-11.	m of endoctatin for canc	er gene therapy	. selective
SL	Yi C, Huang Y, Quo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on metanoma. Acta Pharmacol Sin. 2005 May.26(5):629-34.									
						,				
										<u></u>
								-		
EXAMINER /Scott Long/						DATE CONSIDERED	10/1	7/2006		
• EXAMINER citation if not i	Initial if refe n conformance	erence considered, where and not considered.	hether or not o Include copy	citation is in conform of this form with ne	uance with MP	EP 609. Draw line through tion to applicant.				